Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature Communications
November 06, 2019 05:33 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, November 6, 2019 – A paper discussing recent preclinical advances of Bavarian Nordic’s (OMX: BAVA, OTC: BVNRY) novel cancer immunotherapy platform was published today in the...
Nylige fremskridt for Bavarian Nordics kræftimmunterapiplatform er optaget i Nature Communications
November 06, 2019 05:33 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. november 2019 – En videnskabelig artikel, der redegør for nylige prækliniske fremskridt for Bavarian Nordics (OMX: BAVA) kræftimmunterapiplatform, blev i dag offentliggjort i...
Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the Congo
October 31, 2019 08:24 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, October 31, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that its partner Janssen Pharmaceutical Companies of Johnson & Johnson will donate up to 500,000...
Bavarian Nordic og Janssens ebolavaccine tages i brug i kampen mod virusudbruddet i den Demokratiske Republik Congo
October 31, 2019 08:24 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 31. oktober 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag at selskabets partner, Janssen Pharmaceutical Companies of Johnson & Johnson, vil donere op mod 500.000 doser...
Bavarian Nordic A/S - Indkaldelse til ekstraordinær generalforsamling
October 25, 2019 09:16 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 25. oktober 2019 – I overensstemmelse med vedtægternes §§ 10 og 13 indkaldes herved til ekstraordinær generalforsamling i Bavarian Nordic A/S: 27. november 2019 kl. 15:30 på...
Bavarian Nordic A/S – Notice Convening Extraordinary General Meeting
October 25, 2019 09:16 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, October 25, 2019 – Pursuant to Articles 10 and 13 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to an Extraordinary General Meeting...
Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline
October 21, 2019 02:59 ET
|
Bavarian Nordic A/S
Acquisition of Rabipur/RabAvert and Encepur which have strong positions in attractive marketsAccelerates our vision by 3 years to become a leading and profitable vaccine companyExploits significant...
Bavarian Nordic offentliggør transformerende køb af to markedsførte vacciner fra GlaxoSmithKline
October 21, 2019 02:59 ET
|
Bavarian Nordic A/S
Køb af Rabipur/RabAvert og Encepur med stærk positionering på attraktive markederFremskynder visionen med 3 år ved at blive et ledende og profitabelt vaccineselskabSikrer udnyttelse af væsentlige...
Bavarian Nordic Updates on Phase 2 Study of CV301 in Bladder Cancer
October 18, 2019 10:16 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, October 18, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the stage 1 of the Phase 2 study evaluating the combination therapy of its cancer...
Bavarian Nordic opdaterer omkring fase 2-forsøget med CV301 i blærekræft
October 18, 2019 10:16 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 18. oktober 2019 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at den første del af fase 2-forsøget, der undersøger kombinationen af selskabets immunterapikandidat,...